SCHEMBL5041804

SCHEMBL5041804

CCOC(=O)C(Cc1ccccc1)N(C)S(=O)(=O)c1ccc(N)cc1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADAMTS5 Q9UNA0 1/20 0.55
ALDH1A1 P00352 4/20 0.44
HPGD P15428 1/20 0.44
POLB P06746 1/20 0.43
NR3C1 P04150 1/20 0.43
GAA P10253 1/20 0.43
ACHE P22303 1/20 0.42
MMP8 P22894 1/20 0.42
TP53 P04637 1/20 0.42
BACE1 P56817 1/20 0.41
PTAFR P25105 1/20 0.41
LMNA P02545 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA9 Q16790 1/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5040765 0.87 ADAMTS5 (0.52) ADAMTS5ALDH1A1HPGDPOLBGAA
Hydrochloric Acid SCHEMBL5040760 0.86 ADAMTS5 (0.51) ADAMTS5ALDH1A1HPGDPOLBGAA
SCHEMBL5040523 0.85 KMT2A (0.54) ADAMTS5ALDH1A1HPGDNR3C1TP53
SCHEMBL28644268 0.81 ADAMTS5 (0.57) ADAMTS5ALDH1A1POLBGAATP53
SCHEMBL5573300 0.77 ADAMTS5 (0.73) ADAMTS5POLBGAACA12CA9
SCHEMBL5573297 0.77 ADAMTS5 (0.73) ADAMTS5POLBGAACA12CA9
SCHEMBL9595768 0.76 PTAFR (0.53) ADAMTS5ALDH1A1HPGDPOLBTP53
SCHEMBL15805201 0.76 ALDH1A1 (0.56) ALDH1A1HPGDPOLBGAAMMP8
SCHEMBL8919925 0.76 POLB (0.48) ADAMTS5ALDH1A1HPGDPOLBACHE
SCHEMBL4261026 0.76 PTPN1 (0.54) ADAMTS5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1633354-B1 N-(((((1,3-THIAZOL-2-YL)AMINO)CARBONYL)PHENYL)SULFONYL)PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES INST FOR PHARM DISCOVERY INC (US) 2008-01-23 EP disclosed
EP-1633354-B1 N-(((((1,3-THIAZOL-2-YL)AMINO)CARBONYL)PHENYL)SULFONYL)PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES INST FOR PHARM DISCOVERY INC (US) 2008-01-23 EP disclosed
EP-1633354-A2 N-(((((1,3-THIAZOL-2-YL)AMINO)CARBONYL)PHENYL)SULFONYL)PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES The Institutes for Pharmaceutical Discovery, LLC (US) 2006-03-15 EP disclosed
US-20040248937-A1 Substituted phenylalkanoic acids for the treatment of diabetes THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC 2004-12-09 US disclosed
WO-2004092146-A2 N- (((((1,3-THIAZOL-2-YL) AMINO) CARBONYL) PHENYL) SULFONYL) PHENYLALANINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF DIABETES THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248937-A1 Substituted phenylalkanoic acids for the treatment of diabetes PTP4A1, PTPRJ, PPM1B ADAMTS5 3529/4885ALDH1A1 123/4885HPGD 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.